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We read with interest the study by Roede et al. [1]
concerning the effectiveness of the short-term
treatment schedule of amoxycillin–clavulanic acid
for type 1 acute exacerbations of chronic obstruc-
tive pulmonary disease (COPD). As in a previous
study of pneumonia by the same group [2], an
attempt is made to answer the fundamental
question concerning the period for which anti-
microbial treatment should be administered in
cases of lower respiratory tract infection. In both
studies, the short 3-day schedule of antibiotic
treatment was as effective as the 10-day schedule,
when an improvement in symptoms was
observed at 3 days. This may be of even greater
interest in primary care, which is a setting in
which over-prescription is common, with a
signiﬁcant rate of non-compliance in cases of
mild and often self-limiting infections.
The results presented are of clinical interest.
However, we feel that the authors should have
been more cautious in formulating their conclu-
sions. A sample size of 225 patients was required
to demonstrate non-inferiority of the 3-day treat-
ment. Nevertheless, the authors concluded that
3-day therapy was an effective alternative to
10-day treatment, based on an analysis of only 46
subjects. Furthermore, the secondary outcome of
bacteriological efﬁcacy was based on an analysis
of only 19 patients [1]. It would have been more
appropriate to conclude that the results sugges-
ted a similar efﬁcacy and that further adequately
powered studies are required to demonstrate the
efﬁcacy of 3-day treatment.
Unlike pneumonia, infection causing an exacer-
bation of COPD is often self-limiting and does not
require antimicrobial treatment. It would there-
fore have been very interesting if a placebo group
had been included to demonstrate whether the
rate of cure in the other two antibiotic treatment
groups was different. Even in the landmark study
by Anthonisen et al. [3] of moderate-to-severe
COPD patients with a mean forced expiratory
volume in 1 s (FEV1) of 33.1%, 55% of the
patients were cured without antimicrobial
treatment. Interestingly, although the patients in
the study by Roede et al. were hospitalised, half
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had an FEV1 of >50%. This is important, as the
role of antibiotics in the treatment of exacerbation
of COPD in patients with mild-to-moderate air-
ﬂow obstruction is currently a subject of debate
[4]. Thus, we feel it would also be interesting to
know, even for small sample sizes, the effective-
ness of short-term schedules based on the severity
of pulmonary function in this study.
Even if a 3-day course of treatment is sufﬁcient,
it may not be possible to generalise these results
to all antibiotics. The GLOBE study [5] demon-
strated the eradication of Haemophilus inﬂuenzae
from sputum in a median time of only 1 day
following treatment with gemiﬂoxacin, but a
signiﬁcantly longer period was required with a
macrolide. In this respect, a more rapid resolution
of symptoms of exacerbation has been demon-
strated following treatment for 5 days with mox-
iﬂoxacin compared with alternative antibiotics
[6]. In another study, a clinical efﬁcacy of up to
93% was observed after treatment of patients
with a predicted FEV1 of >50% with levoﬂoxacin
for only 3 days [7]. In such cases, the shorter
duration of treatment may be related to the speed
of killing bacteria with ﬂuoroquinolones, an
effect that may also be achieved with amoxycil-
lin–clavulanate, but that may not be achieved with
other antibiotics such as macrolides.
An alternative may be to delay the prescrip-
tion of antibiotics, which is an approach that has
been shown to be successful in cases of acute
bronchitis [8]. In such cases, the patient decides
whether to take the antibiotic prescribed if the
symptoms do not improve within a few, nor-
mally 3, days. The use of this approach for
treatment of exacerbations of COPD is also
currently a subject of debate, as several studies
have demonstrated that the earlier the initiation
of therapy, the shorter the duration of the
symptoms [9]. In studies comparing 3-day vs.
10-day treatment regimens, the inclusion of a
placebo group and the possibility of delayed
antibiotic prescription would help to clarify the
role of antibiotics in the treatment of these
patients, particularly those with better lung
function [10]. The use of antibiotics could there-
by be better rationalised, so that they would not
be taken by most of the patients who do not
need them, but rather would be taken by
patients for whom they are indeed necessary.
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